Oncothyreon Inc.’s net losses widened in the first quarter of 2013, a change the company largely attributes to administrative expenses and an increase in research and development.
The Seattle-based biotech reported first-quarter operations losses of $8 million Thursday, compared with $5.7 million for the same period in 2012.
Oncothyreon’s R&D expenses for Q1 2013 increased to $5.8 million from $4.3 million in the first quarter of 2012. During that same period, administrative expenses rose…
Oncothyreon Inc.’s net losses widened in the first quarter of 2013, a change the company largely attributes to administrative expenses and an increase in research and development.
The Seattle-based biotech reported first-quarter operations losses of $8 million Thursday, compared with $5.7 million for the same period in 2012.
Oncothyreon’s R&D expenses for Q1 2013 increased to $5.8 million from $4.3 million in the first quarter of 2012. During that same period, administrative expenses rose…